In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.

With an 11% increase in store c In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1 ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...